Vancouver Sun on MSN
B.C. teen first in world to be cured of rare disease through gene editing treatment
To be the first person in the world cured of chronic granulomatous disease, a rare genetic condition, feels a little surreal ...
Prime Medicine reports positive initial Phase 1/2 trial results for PM359, showing safety and efficacy in treating Chronic Granulomatous Disease. Prime Medicine, Inc. has announced positive initial ...
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic ...
BOSTON--(BUSINESS WIRE)--Ensoma, a genomic medicines company advancing the future of medicine through one-time, in vivo treatments capable of precisely and durably engineering the hematopoietic system ...
First ever clinical evaluation of an in vivo HSC-directed gene insertion therapy aims to restore immune function for people living with X-linked chronic granulomatous disease Ensoma, an in vivo ...
A collaborative effort between investigators at the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) and Massachusetts General Hospital (MGH), a founding ...
CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, ...
-- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity by Day 15 and 66% by Day 30, well above levels believed to be potentially curative -- - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results